Clinical

An oncologist specializing in breast cancer treatment reviews the latest guideline recommendations for systemic therapies in HR+/HER2- breast cancer, comparing the available CDK4/6 inhibitors and discussing considerations for optimal treatment sequencing.

The effectiveness of nirsevimab therapy shows promise against respiratory syncytial virus (RSV)–associated bronchiolitis in a real-world setting.

Chronic obstructive pulmonary disease (COPD) significantly heightens the risk of mortality and hospitalization in patients with heart failure with preserved ejection fraction (HFpEF).

On this episode of Managed Care Cast, we're talking with the author of a study published in the July 2024 issue of The American Journal of Managed Care® that estimates the insurance value of novel Duchenne muscular dystrophy (DMD) treatment.

Social determinants of health (SDOH) factors significantly impact the overall health perceptions of Black and Hispanic ovarian cancer survivors.

Key discussion points for educating patients on infection risk management in PNH care are highlighted.

Medical experts navigate significant challenges associated with PNH treatment.

Investigators hoped to use large-scale proteomics to help predict hypertensive disorders of pregnancy (HDP), using blood proteins obtained from individuals in their first trimester of pregnancy—but success has been elusive.

The therapy led to increased frataxin levels and decreased left ventricular mass in patients with Friedreich ataxia (FA) cardiomyopathy, the authors said.

Atopic dermatitis experts examine factors that impact coverage decisions for atopic dermatitis (AD) treatments, address challenges providers encounter (such as step-therapy and prior authorization) and offer strategies to streamline the prior authorization process for topical AD therapies.

Using the modified Tinkertoy Test (m-TTT), recent findings further the understanding of specific cognitive deficits affecting life skills in individuals with schizophrenia, revealing a critical link between divergent thinking and daily functioning.

An expert consensus by Spanish dermatologists offers treatment recommendations for androgenetic alopecia, the most common cause of hair loss, using a combination of medications and hair transplantation depending on the patient's sex, age, and other factors.

A new case report details the successful use of efgartigimod as a rescue medication in a patient with therapy-refractory myasthenic crisis.

Timothy Caulfield, JD, research director of the Health Law Institute at the University of Alberta, discusses strategies for building trust, overcoming cultural and language barriers, and enhancing interdisciplinary collaboration in pediatric dermatology at the Society of Pediatric Dermatology conference.

With 20 hospitals earning the Honor Roll distinction, the report compared hospitals in 15 specialties and 20 procedures and conditions. Of these, only 160 earned the "Best Hospitals" ranking, signifying excellence in clinical outcomes, nursing care, and patient safety practices.

The biomarker, G-protein-coupled receptor 176 (GPR176), may be a driver in the progression of ovarian cancer and potential target for gene therapy, suggested researchers of a new study.

No significant differences in efficacy or safety of 2 aspirin doses were found between male and female patients for the secondary prevention of atherosclerotic cardiovascular disease (ASCVD).

Overall and site-specific colorectal cancer (CRC) had a negative association with the usage of aspirin.

Experts in dermatology presented ways in which biologic therapies can be given and the duration of treatment when used in pediatric patients with skin conditions.

Patients with myelodysplastic syndrome (MDS) in the treatment arm were more likely to achieve transfusion independence, but the difference vs placebo was not statistically significant.

Liposomal daunorubicin and cytarabine (CPX-351) was effective in relapsed acute myeloid leukemia, but long-term follow-up is needed to determine the extent of the agent's cardiotoxicity.

Ibrahim Aldoss, MD, of City of Hope, discusses promising phase 2 results of the WU-CART-007 trial, demonstrating high efficacy manageable safety for W-T7 in relapsed/refractory T-cell acute lymphoblastic leukemia (ALL)/lymphoblastic lymphoma (LBL).

Pirtobrutinib led to improved outcomes compared with venetoclax in patients with relapsed chronic lymphocytic leukemia (CLL) following covalent Bruton tyrosine kinase inhibitor therapy.

Anna Sureda, MD, PhD, of the Catalan Institute of Oncology, discusses the evolving treatment landscape for patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma.

A small trial by investigators at the National Cancer Institute holds promise to bring personalized cell therapy into the solid tumor arena, after more than a decade of success in blood cancers.